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G-protein-coupled receptors (GPCRs) can modulate
diverse signaling pathways, often in a ligand-specific
manner. The full range of functionally relevant
GPCR conformations is poorly understood. Here,
we use NMR spectroscopy to characterize the con-
formational dynamics of the transmembrane core of
the b2-adrenergic receptor (b2AR), a prototypical
GPCR. We labeled b2AR with
13CH3ε-methionine
and obtained HSQC spectra of unliganded receptor
as well as receptor bound to an inverse agonist, an
agonist, and a G-protein-mimetic nanobody. These
studies provide evidence for conformational states
not observed in crystal structures, as well as sub-
stantial conformational heterogeneity in agonist-
and inverse-agonist-bound preparations. They also
show that for b2AR, unlike rhodopsin, an agonist
alone does not stabilize a fully active conformation,
suggesting that the conformational link between
the agonist-binding pocket and the G-protein-
coupling surface is not rigid. The observed heteroge-
neity may be important for b2AR’s ability to engage
multiple signaling and regulatory proteins.
INTRODUCTION
When first characterized in the 1970s, G-protein-coupled recep-
tors (GPCRs) were often viewed as binary signaling proteins.
Simple two-state models, with inactive (R) and active (R*) states
in equilibrium, could describe most of their known behaviors.
However, functional and pharmacological studies during
the subsequent three decades have revealed many GPCRs to
be very versatile signaling proteins that can modulate the
activity of more than one second messenger system, often in
a ligand-specific manner. These observations suggest that532 Cell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc.GPCRs are dynamic proteins that assume multiple distinct
conformations depending on the bound ligand, the associated
signaling proteins, and the membrane environment (Deupi and
Kobilka, 2010; Yao et al., 2009). Subsequent biophysical and
biochemical studies provided some direct evidence for multiple
conformational states for specific GPCRs (Altenbach et al.,
2008; Liu et al., 2012; Yao et al., 2006), and more recent
progress in GPCR structural biology has provided the first
high-resolution pictures of GPCRs in both inactive and active
states (Rasmussen et al., 2011a, 2011b; Rosenbaum et al.,
2007). These crystal structures represent single snapshots of
just a few conformational states, however, and relatively little
is known about what other conformational states these recep-
tors can adopt, how dynamic each conformational state is,
or how different conformational states are stabilized by binding
of ligands and associated signaling proteins. This uncertainty
poses an obstacle to structure-based drug design for GPCR
targets.
The b2AR is an ideal model system for investigating the role of
GPCR protein dynamics in signaling. The b2AR activates more
than one G protein and signals through at least one G-protein-
independent pathway, arrestin (Rajagopal et al., 2005) (Fig-
ure 1A). There is a rich diversity of available ligands for the
b2AR. These ligands are often characterized as inverse agonists
that suppress basal activity, full agonists that maximally activate
the receptor, partial agonists that produce submaximal activity
even at saturating concentrations, and neutral antagonists that
occupy the orthosteric binding site but do not affect basal
activity (Rosenbaum et al., 2009) (Figure 1B). To complicate
matters further, the efficacy of a ligand may depend on the
downstream signaling pathway used to quantify activity. For
example, carvedilol is an inverse agonist for the b2AR activation
of Gs but is a partial agonist for b2AR activation of arrestin (Wisler
et al., 2007). Finally, the b2AR is the only GPCR that has been
crystallized in both inactive and G-protein-coupled conforma-
tions (Rasmussen et al., 2011b; Rosenbaum et al., 2007).
The dynamic behavior of proteins is well recognized but
often difficult to characterize. Proteins exhibit small-scale
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Figure 1. The b2AR Is a Versatile Signaling Protein
(A) The b2AR interacts with several signaling and regulatory proteins in an agonist-dependent manner. The b2AR can activate the heterotrimeric G proteins Gs and
Gi. G-protein-coupled receptor kinases (GRKs) phosphorylate the agonist-bound receptor, which can subsequently bind to arrestin and be either internalized or
signal through the MAP kinase and other pathways.
(B) The b2AR exhibits basal agonist-independent activation of Gs. Drugs that can suppress basal activity are called inverse agonists (for example, carazolol).
Neutral antagonists (for example, alprenolol) can block binding of other ligands but do not impose any biological response. Agonists can be divided into two
categories: full agonists (for example, BI-167107) and partial agonists. Full agonists produce the full biological response, whereas partial agonists can only
produce a partial biological response even at saturating concentrations. These properties are independent of ligand affinity.
(C) Schematic free energy landscapes illustrating the energy of the receptor along the activation pathway. The top, middle, and bottom panels show the energy
landscape with no ligand bound, with agonist bound, and with both agonist and nanobody 80 (Nb80) bound, respectively. The middle and bottom panels also
show the unliganded landscape as a dashed line for comparison.
(D) The NMR experiments show that agonist binding to the b2AR does not fully stabilize the active conformation, suggesting a relatively weak conformational link
between the agonist binding pocket and the G-protein-coupling surface.
Results from crystal structures ofMetarhodopsin II and double electron-electron resonance (DEER) spectroscopy suggest that covalently bound trans-retinal can
stabilize the active state of the G-protein-coupling surface.
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Figure 2. Positions of Methionines in Active
and Inactive b2AR Structures
(A) Methionine residues shown as sticks in the
active and inactive b2AR crystal structures.
Solid spheres represent the methionine methyl
carbons left in b2AR-D5, whereas dotted
spheres represent methyls of methionines
mutated to other residues in b2AR-D5. The
functional properties of b2AR-D5 are similar to
those of wild-type b2AR (see also Figure S1 and
Table S1).
(B) Structure of b2AR in the crystallographic
inactive conformation (2RH1) seen from the intra-
cellular side. Leu2726.34 and surrounding hydro-
phobic residues are shown as sticks.
(C) Structure of b2AR in the crystallographic active
conformation (3P0G) seen from the intracellular
side.movements at the level of amino acid side chains and larger-
scale movements between domains on timescales ranging
from picoseconds to seconds (Henzler-Wildman and Kern,
2007). As a result, proteins exist in many conformations,
each with a distinct energy resulting from intramolecular
chemical bonds and noncovalent interactions. Overall, the
thermodynamically most favorable conformations predomi-
nate. The most stable conformations correspond to those
structures likely to be captured in X-ray crystallography.
Thus, our view of protein structure is biased toward these
stable conformations. However, the less stable (i.e., less popu-
lated) conformations may also be important for function (Han-
sen et al., 2008).
Protein dynamics are often described in terms of a free
energy landscape (Figure 1C), where the energy is plotted as
a function of conformation. The depths of the energy wells
determine the relative populations of the various conforma-
tional states at equilibrium, and the heights of the barriers
determine the rates of transitions between states (Deupi and
Kobilka, 2010). By employing nuclear magnetic resonance
(NMR) spectroscopy to study dynamic properties of the
b2AR, we can begin to understand its energy landscape. In
this paper, we present evidence for several conformational
states that have not been observed crystallographically. In
particular, our studies reveal an alternative inactive conforma-
tional state, which exchanges slowly with the crystallographi-
cally observed inactive state in the presence of inverse
agonists or in the absence of a ligand. Our studies also demon-
strate that a receptor bound to an agonist alone is structurally
heterogeneous and that the most populated conformation
differs from both the inactive conformational states that domi-
nate in inverse-agonist-bound and unliganded receptors and
the active states that dominate when the receptor is bound to
both an agonist and a G-protein-mimetic nanobody (Figure 1D).534 Cell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc.We use molecular dynamics simulations
to provide a structural framework in
which to interpret these results. For the
purpose of illustration and discussion,
we will describe the conformationalensembles induced by different ligands using the simple energy
landscapes shown in Figure 1C.
RESULTS AND DISCUSSION
Application of NMR Spectroscopy and MD Simulations
to Characterize Conformational Dynamics in the b2AR
NMR spectroscopy has been used to study the structure and
dynamics of a range of proteins. Specific labeling of methyl
groups, such as the ε-methyl of methionine (13CH3ε-Met), has
been shown to be an effective method for studying large mole-
cules by NMR (Beatty et al., 1996; Bose-Basu et al., 2004; Della-
Vecchia et al., 2007). 13CH3ε-Mets are ideal NMR probes for
high-molecular-weight proteins because the length and flexibility
of the methionine side chain compensates for the slow tumbling
of large proteins, improving the resolution and sensitivity of the
spectra (Tugarinov et al., 2003).
13CH3ε-Mets are also excellent NMR probes for studying
conformational changes in the b2AR. The b2AR has nine methio-
nine residues (not counting the N-terminal methionine, which is
removed by signal peptidase) dispersed throughout its primary
sequence,many of which are found in the transmembrane region
of the receptor (Figure 2A and Figure S1A available online). This
region has not been accessible to study using fluorescence
spectroscopy or fluorine NMR, which require the addition of
small-molecule probes to surface-exposed cysteines (Liu
et al., 2012; Yao et al., 2006).
The location of a peak (also known as the chemical shift or
resonance) representing a 13C-methyl group in an NMR spec-
trum is dependent on the microenvironment of the methyl in
the protein. In proteins, the protons and carbon of 13C-methyls
experience a wide variety of chemical environments depending
on local and global protein structure and on solvent exposure
(Butterfoss et al., 2010; Wishart, 2011). As a result, the position
of an NMRpeak is very sensitive to changes in protein conforma-
tion or protein-protein interactions. NMR is also sensitive to
molecular motion; if a methyl group is in conformational
exchange between two structurally distinct states, the appear-
ance of the peak is dependent on the timescale at which this
exchange occurs (Mittermaier and Kay, 2009). If the exchange
between the two states is slow (several milliseconds or more),
one observes two distinct peaks representing the two different
environments, whereas if the exchange is fast (nanosecond to
microsecond), one observes a peak at the weighted average of
the two chemical shifts. For methyl groups that exchange
conformations in the intermediate time regime (microseconds
to milliseconds), the corresponding peaks will be very weak or
not visible (Mittermaier and Kay, 2009). Therefore, NMR spectra
can provide information about changes in protein structure as
well as the timescales over which the changes occur.
To provide a structural framework for interpreting the results of
our NMR experiments, we utilized atomic-level long timescale
MD simulations of the b2AR. We analyzed an extensive set of
simulations—including some reported previously (Dror et al.,
2011a, 2011b) and others performed especially for this
purpose—with a focus on specific receptor regions and dynamic
properties probed by the NMR experiments. These simulations
were performed on Anton (Shaw et al., 2009), a special-purpose
computer designed to accelerate classical MD simulations by
orders of magnitude, allowing them to describe conformational
changes on much longer timescales than previously possible.
Modified b2ARs for NMR Experiments
To study specific regions of the b2AR, we prepared a modified
b2AR (b2AR-D5M) by making the following mutations: M40L,
M96T, M98T, M156L, and M171L. These methionines, which
face the exterior of the receptor (Figure 2A), were mutated to
simplify the spectrum and eliminate signals from 13CH3ε-Mets
that do not undergo structural changes when comparing active
and inactive structures. Antagonist and agonist binding affinities
were determined for b2AR-D5M and other modified receptors
described below based on saturation and competition binding
experiments (see Figures S1B and S1C and Table S1). We also
determined that b2AR-D5M couples efficiently to the G protein
Gs as determined by a GTPgS-binding assay (Figure S1D). We
retained Met361.35 at the extracellular end of TM1 as a reference
because it is facing outward in a region of the protein that does
not undergo conformational changes upon activation. The other
three methionines that we retained—Met822.53, Met2155.54, and
Met2796.41—are especially interesting with regards to ligand
binding and signal transduction (Figures 2A and S1A).
Met822.53 is found just below the ligand-binding pocket in TM2
(Figure 2A) and is within 4 A˚ of several amino acids that directly
interact with both agonists and antagonists. Met822.53 is there-
fore sensitive to changes in the chemical environment around
the ligand-binding pocket. Met2155.54 and Met2796.41 are
located between the ligand-binding pocket and the cytoplasmic
ends of TM5 and TM6, respectively (Figure 2A). The cytoplasmic
ends of TM5 and TM6 undergo relatively large structural changes
to accommodate binding to Gs and to Nb80 (Figure 2A).
To enable characterization of the dynamic features at the cyto-
plasmic end of TM6, we also created a L272Mmutation in b2AR-D5M (b2AR-D5M-L272M). In the inactive-state crystal structure
of the b2AR, Leu272
6.34 packs into a pocket formed by residues
in TM5 and TM3 (Figure 2B), whereas in active-state structures,
Leu2726.34 is solvent exposed (Figure 2C) and does not interact
with either Nb80 or Gs. The L272A mutation is known to lead to
constitutive activity (Samama et al., 1993) and structural insta-
bility (Gether et al., 1997), but we expected that Met would be
a better structural substitute for Leu, causing little constitutive
activity. Indeed, the L272M mutation in b2AR-D5M resulted
in only a modest (4-fold) increase in agonist binding affinity (Fig-
ure S1B and Table S1), whereas the L272A mutation in wild-type
b2AR leads to an 20-fold increase in binding affinity (Samama
et al., 1993). The agonist binding affinity for b2AR-D5M-L272M
is indistinguishable from the unmodified b2AR and exhibits
none of the biochemical instability associated with the constitu-
tively active mutant L272A (Gether et al., 1997).
b2AR-D5M and b2AR-D5M-L272M were expressed in methio-
nine-deficient media supplemented with 13CH3ε-methyl-labeled
methionine (13CH3ε-Met) and purified to homogeneity (see
Experimental Procedures). The 13CH3ε-Met resonances from
b2AR-D5M and b2AR-D5M-L272M appear in a region of the
cHSQC spectrum that is free of signals from buffer, detergent,
or unlabeled b2AR protein (Figure S2). We assigned methionines
36, 82, 215, and 279 in b2AR-D5M by mutagenesis (Figure S3).
13CH3ε-Met NMR spectroscopy was recently used to investigate
the effect of agonists and partial agonists on the structure of the
b2AR, and the spectral assignment of specific
13CH3ε-Met reso-
nances is in agreement with ours (Kofuku et al., 2012).
Ligand-Specific Changes in cHSQC Spectra of the b2AR
Figures 3 and 4 show the assigned cHSQC spectra of 13CH3ε-
Met-b2AR-D5M and
13CH3ε-Met-b2AR-D5M-L272M under the
following conditions: unliganded, bound to the inverse agonist
carazolol, bound to the high-affinity agonist BI-167107, and
bound to both BI-167107 and the G-protein-mimetic nanobody
Nb80. Both carazolol and BI-167107 have very long dissociation
half-lives (Rasmussen et al., 2007, 2011a). For NMR experi-
ments, these ligands were added in a 10-fold stoichiometric
excess over receptor at concentrations that far exceed their
Kd/Ki values. In studies done with purified b2AR-D5M under
these conditions, the agonist BI-167107 has a dissociation
half-life of 403 min and an association half-life of less than
4.4 min (Figure S1D). We therefore do not expect to observe
conformational heterogeneity due to ligand dissociation and re-
association. All spectra were obtained at room temperature. We
usedNb80 as a substitute for theG protein because the substan-
tially smaller size of Nb80 leads to higher resolution in the result-
ing NMR spectra (large complexes tumble more slowly, leading
to line broadening). Recent crystal structures have shown that
the receptor conformations stabilized by Nb80 and the G protein
(Gs) are very similar (Rasmussen et al., 2011a, 2011b).
The peaks observed in our two-dimensional (2D) spectra are
relatively broad and irregularly shaped. This is due in part to
the large size of b2AR-D5M together with its detergent micelle
but may also reflect inherent conformational heterogeneity.
The Met361.35 peak is the most intense peak in all
spectra (Figures 3 and S3A). This was expected, as Met361.35
is the most solvent-exposed methionine in b2AR-D5M andCell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc. 535
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Figure 3. Ligand-Specific Effects on the
HSQC Spectrum of 13C-Met-b2AR-D5
(A–D) Carbon-HSQC of spectra of b2AR-D5 were
obtained under the following conditions: (A)
unliganded, (B) bound to the inverse agonist
carazolol, (C) bound to the agonist BI-167107,
and (D) bound to BI-167107 and the G-protein-
mimetic Nb80. In contrast to the complex spectra
of unmodified b2AR containing nine methionines
(see Figure S2A), resonances for individual methi-
onines are clearly distinguishable in the spectra
for b2AR-D5. Assignments of
13C-Met resonances
in b2AR-D5 were made by obtaining spectra
of b2AR-D5+M36L, b2AR-D5+M82V, and b2AR-
D5+M215I (see Figure S3). Spectra A–C were
recorded at 25C on a 900 MHz Bruker spec-
trometer. Spectrum D was recorded at 25C
on an 800 MHz Varian spectrometer. See
Table S2 for details about acquisition of NMR
spectra. In all spectra, a peak at 1.4 ppm [1H] and
19.2 ppm [13C] is observed, and we expect this
peak represents nonmethionine methyl groups
in the receptor that are observed because of
the natural abundance 13C in the sample (see also
Figure S2B).b2AR-D5M-L272M. Inactive- and active-state b2AR crystal
structures show that TM1 does not undergo a major conforma-
tional change during activation, so it is not surprising that we
observe no ligand-specific change in the chemical shift for
Met361.35. Met361.35 therefore serves as a reference for the re-
maining 13CH3-Met resonances.
Unliganded and Inverse-Agonist-Bound b2AR Are
Conformationally Heterogeneous
With the exception of Met822.53, each of themethionines present
in b2AR-D5M corresponds to a single peak in the spectra of the
unliganded receptor (Figures 3 and S3). The positions of these
peaks do not change upon binding to the inverse agonist carazo-
lol, and they thus likely correspond to the inactive state of the
receptor (Figure 3).
In contrast, Met822.53, which is located just below the ligand-
binding pocket in TM2 (Figure 2A), is represented by two peaks
of moderate intensity (and possibly a third weak peak) in the un-
liganded and inverse-agonist-bound samples (Figures 3 and
S3B). The observation of two peaks from Met822.53 suggests
that its 13CH3ε-methyl is detecting at least two conformations
that exchange on a millisecond or longer timescale. Molecular
dynamics simulations indicate that, although the Met822.53
side chain transitions between different rotameric states, it
does so very rapidly, on a nanosecond timescale, which is far
faster than the millisecond timescales that would lead tomultiple
peaks in NMR spectra (Figure S4). The two peaks thus probably
reflect larger structural changes in the receptor.
Several factors might contribute to the presence of dual
Met822.53 peaks, including changes to the rotameric state of
Trp2866.48 or the protonation state of Asp792.50. Long-timescale
molecular dynamics simulations offer an alternative explanation.536 Cell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc.In certain simulations of the crystallographic inactive state (both
with the inverse agonist carazolol bound and with no ligand
bound), we observed a transition to an alternative conformation
in which the intracellular half of TM7 (Asn3187.45–Cys3277.54,
including the conserved NPxxY motif) rotates 40 clockwise
relative to the crystal structure (viewed from the intracellular
side) and shifts toward the center of the helical bundle by 3 A˚
(Figures 5A and 5B). This conformational change would allow
the ε-methyl Met822.53 to move into a more hydrophobic envi-
ronment and increases its distance to the aromatic ring of
Trp2866.48 from 4.5 A˚ to 7 A˚ (Figure 5C), which would be ex-
pected to alter its chemical shift. The conformational change
does not alter the chemical environments of the other methio-
nines present in b2AR-D5M and b2AR-D5M-L272M. Exchange
between these two inactive conformations appears to be slow.
In roughly 400 ms of unbiased simulation (split roughly evenly
between the crystallographic inactive and alternative conforma-
tional states), we have observed three transitions from the crys-
tallographic conformation to the alternative conformation and
a single reverse transition. Millisecond-timescale exchange
between these two conformations in the NMR experiments
seems quite plausible, given that rates estimated by MD simula-
tions often differ from experimentally measured ones by several
fold (Dror et al., 2010) and that the receptor is surrounded by
lipids in the simulations and detergent in the experiments. To
further probe these long-timescale events, we performed
temperature-acceleratedMD simulations of the carazolol-bound
receptor. These simulations exhibited repeated transitions
between the crystallographic inactive and alternative conforma-
tions, with the crystallographic conformation present in a slightly
higher population (Figure S4D). It should be noted that, although
the timescale of transitions between inactive states observed in
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Figure 4. Ligand-Specific Effects on the
HSQCSpectrumof 13C-Met-b2AR-D5-L272M
(A–D) Carbon-HSQC spectra of b2AR-D5-L272M
were obtained under the following conditions: (A)
unliganded, (B) bound to the inverse agonist
carazolol, (C) bound to the agonist BI-167107,
and (D) bound to BI-167107 and the G protein
mimetic Nb80. Spectra were recorded at 25C
on an 800 MHz Varian spectrometer (see Table S2
for details about acquisition of NMR spectra).
For the spectra with BI-167107 and BI-167107
plus Nb80 bound, a 1D slice illustrates the splitting
of the Met2726.34. The red line represents the
carbon chemical shift where this 1D slice was
taken.MDsimulations is consistent with our NMR results, we cannot be
certain that either state is responsible for the observed chemical
shifts for M82.
In Figure 1C, we illustrate the conformational substates
observed with NMR as a pair of local minima, corresponding to
the crystallographic and alternative inactive states, within the
larger well representing inactive conformations. The local
minima are separated by a relatively large energy barrier that is
responsible for the slow exchange observed in NMR experi-
ments. These inactive substates are themselves dynamic; within
each, for example, our simulations exhibit fast exchange
between conformations with and without the ionic lock between
TM3 and TM6 formed (Dror et al., 2009).
Although carazolol binding does not change the relative inten-
sities of the two main Met822.53 peaks, it does induce a small
shift in their position relative to the unliganded condition (Fig-
ure 3). The aromatic component of carazolol is relatively far
away (7–9 A˚) from 13CH3ε-Met82
2.53 and would thus not be ex-
pected to influence its chemical shift (Figure S4A). The shift of
the Met822.53 peaks upon carazolol binding might reflect subtle
changes around the ligand-binding pocket propagated to
Met822.53 through Trp2866.48 and Tyr3167.43 (Figure S4C).
Agonists Do Not Fully Stabilize an Active Conformation
of the b2AR
Not surprisingly, all peaks apart from the one corresponding to
Met361.35 change substantially upon receptor activation, as evi-
denced by the spectra of receptor bound to both a strong
agonist and the nanobody (BI-167107+Nb80) (Figures 3 and 4).
Under this condition, each methionine has one corresponding
peak. The peak representing Met2796.41 is best seen in Fig-
ure S3B, where the overlapping Met822.53 has been mutated,
or in Figure S5, which shows a one-dimensional (1D) slice. TheCell 152, 532–542peaks are broad and irregular, suggest-
ing that, when in complex with Nb80,
the b2AR exists in predominantly one
conformation with substantial dynamic
behavior, as indicated by a single broad
energy well in Figure 1C.
When only the agonist BI-167107 is
bound (Figures 3 and 4), the spectra
indicate the presence of a receptorconformation distinct from those that dominate either when
both BI-167107 and Nb80 are bound or when an inverse agonist
or no ligand are bound. In the presence of BI-167107 alone,
the peaks corresponding to Met822.53, just below the
binding pocket, and Met2726.34, at the cytoplasmic end of
TM6, display only subtle changes from those observed in the
BI-167107+Nb80 condition. In contrast, the peaks correspond-
ing to the residues between the binding pocket and G-protein-
coupling regions change substantially; the Met2155.54 peak
becomes weaker and shifts upfield, whereas the Met2796.41
peak disappears from spectra of b2AR-D5M.We cannot exclude
the possibility that a peak or peaks representing Met2796.41 in
the presence of agonist alone may overlap with that for
Met822.53. Very weak peaks are observed at 2.07 [1H] and 17.1
parts per million (ppm) [13C] and 2.1 [1H] and 16.5 ppm [13C] in
the spectrum of b2AR-D5M-M82V (Figure S3B).
These results indicate that, with only a strong agonist bound,
the receptor does not simply populate a mixture of the crystallo-
graphically observed active and inactive conformations. Instead,
it populates a set of conformations in which the chemical envi-
ronment of Met822.53 and Met2726.34 is similar to the active
conformation of the BI-167107+Nb80 condition, but that of
Met2155.54, and possibly Met2796.41, is different. Not only do
we observe a different set of conformations around Met2155.54
and Met2796.41 when comparing agonist alone with no ligand
and agonist+Nb80, we observed differences in peak intensities
(Figure 6A). These observations can be interpreted using an
energy landscape (Figure 1C). Our results suggest that, in the
presence of agonist alone, the receptor transitions between
several substates on an intermediate timescale, thus the weaker
signals. Nb80 appears to stabilize a more uniform conforma-
tion as suggested by the peak volume of the NMR signals for
Met822.53, Met2155.54, and Met2726.34 (Figure 6A)., January 31, 2013 ª2013 Elsevier Inc. 537
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Figure 5. Alternative Inactive State Ob-
served in Unliganded and Inverse-Agonist-
Bound MD Simulations May Explain Dual
Met822.53 Peaks
(A) The transition from the crystallographic inactive
conformation (orange, 2RH1) to the alternative inac-
tive conformation (gray, snapshot from MD simula-
tion) involves a rotation of the intracellular part of
TM7. Pro3237.50 moves 4 A˚ toward TM2 into the
space between Asp792.50 and Asn511.50, displacing
a conserved water molecule linking these two resi-
dues (Pardo et al., 2007), and Tyr3267.53 adopts the
trans c1 rotamer, pointing its phenol hydroxyl down
toward the ionic lock between TM3 and TM6.
Ser3197.46 shifts2 A˚ toward Trp2866.48 and forms a
hydrogen bond, and its displacement opens a small
hydrophobic cavity at the interfaceof TM1, TM2, and
TM7, into which Met822.53’s ε-methyl group docks.
(B) Distances between the a-carbon atoms of
Ser3197.46 and Ile471.46 (black) and Pro3237.50
and Leu757.46 (red) over the course of a simulation
of b2AR, which transitions from the crystallo-
graphic inactive conformation to the alternative
inactive conformation after 1.93 ms. The bar at
the bottom of the plot illustrates when we see the
crystallographic inactive conformation (orange)
and the alternative inactive conformation 2 (gray).
(C) Distributions of the distance from Cε of Met822.53 to the closest nonhydrogen atom in the aromatic ring of Trp2866.48, plotted for the crystallographic inactive
and alternative inactive conformation. See Figure S4 for additional analysis of these two inactive conformations and Table S3 for additional details about
molecular dynamics experiments.Again, long-timescale simulations can provide a possible
structural explanation consistent with this data. As described
previously (Dror et al., 2011a), b2AR with BI-167107 bound, but
without an intracellular binding partner, transitioned spontane-
ously from the crystallographic active state to the crystallo-
graphic inactive state in simulation. En route, it pauses in an
intermediate state in which TM7 adopts a conformation similar
to that seen in inactive structures, but TM5 and TM6 do not
(Figures 6 and 7). In this intermediate conformational state, as
in the crystallographic state, the intracellular end of TM6 main-
tains its separation from TM3, but the intracellular ends of TM5
and TM6 display substantial mobility.
If we assume that the receptor preferentially populates the
intermediate state when bound only to a strong agonist, the
mobility observed in the intermediate state (Figure 7) explains
the weakness of the Met2155.54 peak and particularly the
Met2796.41 peak. Met2796.41, whose side chain points toward
TM3 in the inactive crystal structure and toward TM5 in the active
crystal structure, displays the greatest mobility in simulations of
the intermediate state; its side chain not only transitions between
its active and inactive conformations but frequently points out of
the helix bundle into the lipids (Figure 7). Tyrosine Tyr2195.58, just
below Met2155.54, also adopts two distinct side-chain rotamers.
The region of the receptor just above residues Met2796.41 and
Met2155.54 and just below the binding pocket also displays
substantial mobility in the intermediate state. This connector
region (Dror et al., 2011a), particularly residues Phe2826.44 and
Ile1213.40, displays a substantially different conformation in
active and inactive crystal structures (Rasmussen et al., 2011b)
(Figure 2). In the intermediate state of the receptor, this region538 Cell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc.toggles between its two crystallographically observed confor-
mations on timescales of a few microseconds in simulation; by
contrast, it is locked in its inactive-like conformation in inac-
tive-state receptor simulations, and it adopts a predominantly
active-like conformation in active-state simulations. The ob-
served fluctuations of the Phe2826.44/Ile1213.40 connector region
in the intermediate state would also be expected to weaken the
Met2796.41 andMet2155.54 NMR peaks; in particular, these inter-
mediate-timescale fluctuations cause variations in the distance
from both Met2796.41 and Met2155.54 to the aromatic ring of
Phe2826.44 (Figures 6B, 6C, and 7).
Whereas the intracellular end of TM6 adopts a broader range
of conformations in the intermediate state than in the active state
in simulation, the chemical environment of Leu2726.34 changes
little; it consistently points out into the lipid bilayer. This is consis-
tent with the NMR spectra, where the Met2726.34 peaks are
similar in the BI-167107- and BI-167107+Nb80-bound condi-
tions. It also explains the strength of the Met2726.34 peak under
these conditions.
The close similarity of the Met822.53 peak in the BI-167107-
bound and BI-167107+NB80-bound NMR spectra suggests
that, in the presence of a strong agonist, the chemical environ-
ment around Met822.53 near the binding pocket is very similar
to that in the fully active-like conformation. This suggests that
the conformational coupling between the binding pocket and
the cytoplasmic ends of TMs 5 and 6 is relatively weak and is
in agreement with simulations showing that the conformation
of the ligand-binding pocket is only loosely coupled to the
conformation of the remainder of the receptor (Dror et al.,
2011a). However, it should be noted that the absence of
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Figure 6. Agonist Binding Promotes Conformational Heterogeneity around Met2155.54 and Met2796.41
(A) Peak volumes for individual methionines. Automated 2D line-shape fitting was performed on the spectra using NMRpipe (Delaglio et al., 1995). From the
line-shape analysis, volumes of the different peaks were extracted. The peak volumes were normalized to the peak volume of Met361.35. After extracting peak
volumes, we estimated their uncertainties by evaluating the root mean square deviation of the volumes of ten peaks chosen from regions of the spectrum
where no signal could be detected in the 2D spectrum, and the uncertainties are shown as error bars. For Met822.53, the peak volumes in the carazolol and the
unliganded state are averages of peak intensities of the twomost intense Met822.53 peaks. Although NB80 would be expected to reduce tumbling of the receptor
in solution and thereby weaken signals, we see signals intensify, suggesting a stabilization of the receptor and a more uniform distribution of conformations
compared to the agonist bound form (see also Figure S5).
(B) Region around Met2155.54 and Met2796.41 shown for the active (green, 3P0G) and inactive (orange, 2RH1) structures of b2AR. Met215
5.54 and Met2796.41 and
aromatic residues in the vicinity of Met2155.54 and Met2796.41 are shown as sticks. Arg1313.50 and Leu2726.34 are also shown as sticks.
(C) Simulations of b2AR starting in the active conformationwith Nb80 removed spontaneously transition back to the inactive conformation. Top two plots illustrate
a transition from the active conformation to the inactive conformation during an MD simulation (adapted from Figure 2 of Dror et al. [2011a]). The transition starts
with the rearrangement of TM7 into its inactive conformation, as illustrated by the plot of TM7’s RMSD to the inactive crystal structure; subsequently, TM6moves
inward toward TM3, as illustrated by the plot of distances between TM3 (Ca of Arg1313.50) and TM6 (Ca of Leu2726.34). We call the state between the re-
arrangement of TM7 and the inwardmovement of TM6 the intermediate state. The bar in the bottom of the plot illustrates what part of the simulation is considered
the active (green), intermediate (blue), and inactive (orange) state.
The bottom four plots illustrate the distance distributions during the simulation between two NMR probes (Met2155.54 or Met2796.41) and two nearby aromatic
residues (Tyr2195.58 or Phe2826.44). The distance distribution of the active conformation is based on simulations of b2AR with BI-167107 and Nb80 bound; the
inactive state is based on simulations of the carazolol bound receptor; and the intermediate state is based on simulations with only BI-167107 bound, as
illustrated in the two top plots. See Table S3 for additional details about molecular dynamics experiments.a chemical shift for Met822.53 does not exclude the possibility of
a conformational change in the binding pocket that does not alter
the chemical environment of Met822.53.
We note that, although both our NMR data and the simulations
suggest that an intermediate state is more stable than the active
state when only the strong agonist BI-167107 is bound, the simu-lations—unlike the NMR data—suggest that the inactive state is
even more stable under these conditions (Dror et al., 2011a).
These simulation results are consistent with a b2AR crystal struc-
ture with only an agonist bound (Rosenbaum et al., 2011), which
closely matches the inactive structure. These differences
suggest that the relative populations of the various states mayCell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc. 539
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Figure 7. Conformational Diversity in Inac-
tive, Active, and Intermediate States
Snapshots from MD simulations are shown every
18 ns. Met2155.54, Met2796.41, Tyr2195.58, and
Phe2826.44 are shown as sticks. The top shows
snapshots from a crystallographic-inactive-state
simulation with carazolol bound. The middle
shows snapshots from an active-state simulation
with BI-167107 and Nb80 bound. The bottom
shows frames from the intermediate state (blue),
with only BI-167107 bound. In the bottom panel
we also show the backbone of crystallographic
inactive (orange) and active (green) states.be highly sensitive to environmental conditions, including lipids/
detergent, temperature, etc. Indeed, minor changes in the ener-
getics of the different conformational states (e.g., 1–2 kcal/mol)
can have substantial effects on their relative populations.
Conclusions
Crystal structures provide snapshots of the b2AR at the begin-
ning and end of the activation process. The full range of function-
ally relevant conformations, however, is difficult or perhaps even
impossible to characterize by crystallography. In an effort to
investigate the process of receptor activation, we used NMR
spectroscopy to monitor the chemical environment of native
methionines strategically located between the ligand-binding
pocket and the G-protein-coupling interface. Our studies show
that the conformational link between the ligand-binding pocket
and the G-protein-coupling interface of the b2AR is not rigid.
The results are compatible with a model (Figure 1D) whereby540 Cell 152, 532–542, January 31, 2013 ª2013 Elsevier Inc.agonist binding destabilizes the inactive
state but does not stabilize the fully active
conformation observed in the b2AR-Gs
complex. Instead, binding of a high-
affinity, high-efficacy agonist is associ-
ated with conformational heterogeneity
that may be important for allowing the
b2AR to engage several alternative
signaling or regulatory proteins depend-
ing on the physiological context (Gs, Gi,
kinases, and arrestins, Figure 1A). This is
in agreement with recent biophysical
studies that suggest biased agonists
that preferentially activate the arrestin
pathway may have a more limited effect
on receptor structure (Kahsai et al.,
2011; Liu et al., 2012; Rahmeh et al.,
2012).
Our studies highlight the complex role
of protein dynamics in signal transduction
and raise questions about the universality
of the structural changes underlying
GPCR signal transduction. Although
many aspects of GPCR structure appear
to be highly conserved, the dynamic
properties we observe may reflect ourchoice of receptor, its environment, or the specific ligands we
employed. Rhodopsin has been the most extensively studied
GPCR model system, and there is a wealth of structural and
biophysical data that characterize the process of activation
(Farrens, 2010; Hofmann et al., 2009; Hubbell et al., 2003).
Several lines of evidence suggest that rhodopsin is somewhat
less dynamic than other GPCRs (Figure 1D). Covalently
bound trans-retinal, for example, appears to be effective at
stabilizing the active state of rhodopsin even in the absence of
a G protein (Figure 1D), as shown by recent crystal structures
of Metarhodopsin II and double electron-electron resonance
(DEER) spectroscopy studies (Choe et al., 2011; Altenbach
et al., 2008). This, together with the lack of constitutive activity,
reflects its highly specialized role in detection of light. For
GPCRs activated by peptide ligands, it is possible that a more
extensive interface between GPCR and agonist might reduce
structural heterogeneity. The effect of the lipid environment
and associated signaling proteins (including other GPCRs)
will likely also contribute to protein dynamics. Further investiga-
tion will be necessary to elucidate such variations and their
importance in both cellular signal transduction and GPCR drug
design.
EXPERIMENTAL PROCEDURES
NMR Spectroscopy of 13C-ε-methyl-Met-b2AR
Between 15 and 20 l of Sf9 cells were infected by baculovirus encoding one of
the b2AR constructs described (see more details in Extended Experimental
Procedures) and were grown in methionine-deficient media with 13C methyl-
labeled methionine added into the media at 250 mg/l concentration. Subse-
quently, the cells were lysed, and the receptor was purified by antibody affinity
chromatography followed by ligand affinity chromatography and then a final
antibody chromatography step.
The receptor was dialyzed twice against a buffer containing 20 mM HEPES
(pH 7.5), 100 mM NaCl, and 0.1% DDM and was prepared in 98% D2O and
concentrated to a final volume of 270 ml.
NMR
The HSQC pulse sequence used is a modified version of the basic HC-HSQC
experiment as described in Bokoch et al. (2010). Data were acquired on the
800 MHz Varian INOVA spectrometer at Stanford Magnetic Resonance Labo-
ratory (SMRL) and on the 900 MHz Bruker Avance 2 at the Central California
900 MHz NMR Facility.
For all the samples, except the b2AR-365N-construct samples, 128 complex
t1 points were collected; for the b2AR-365N sample, only 64 complex t1 points
were collected (see Table S2). To allow temperature equilibration, 64 steady-
state scans preceded data acquisition, and a relaxation delay of 1.5 s was
inserted to allow spin to relax back to equilibrium. The spectra were processed
and visualized using NMRPipe/NMRDraw (Delaglio et al., 1995) software and
NMRViewJ software, respectively. To eliminate horizontal noise from the
very intense detergent methyl peak at 0.85 ppm [1H] and 16.8 ppm [13C], we
used WET suppression of this methyl peak in some of the experiments (see
Table S2). A common threshold, based upon a natural abundance peak at
1.4 ppm [1H] and 19.25 ppm [13C], was chosen for all spectra.
Molecular Dynamics Simulation Methods
We analyzed MD simulations of b2AR totaling 588 ms, including 15 previously
unpublished simulations (Table S3) as well as previously published simulations
(Dror et al., 2011a, 2011b).
We performed all-atom simulations of b2AR under the four primary
conditions of our NMR experiments: unliganded, bound to carazolol, bound
to BI-167107, and bound to both BI-167107 and Nb80. The initial coordinates
of unliganded and carazolol-bound simulations were based on a carazolol-
bound b2AR crystal structure (PDB entry 2RH1). The initial coordinates of
BI-167107-bound simulations, with and without Nb80, were based on the
crystal structure of b2AR bound to BI-167107 and Nb80 (PDB entry 3P0G).
All simulations included an explicitly represented lipid bilayer, water, and salt
ions. We used the CHARMM27 parameter set (MacKerell et al., 1998, 2004)
with a modified lipid force field (Klauda et al., 2010); a modification to Asp,
Glu, and Arg side chains (Piana et al., 2011); and previously designed param-
eters for carazolol, palmitoyl-cysteine, and BI-167107 (Dror et al., 2009; Rose-
nbaum et al., 2011). Simulations were unbiased, apart from two that used
temperature-accelerated MD (Maragliano and Vanden-Eijnden, 2006) to
accelerate sampling of the distance between the centers of mass of the back-
bone atoms of Leu752.46 and Pro3237.50.
For more details on methods andmaterials used for this work, see Extended
Experimental Procedures.
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